Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.
Both tumor-specific CD4(+) and CD8(+) T cells have been identified, and the latter is known as a major effector of adaptive antitumor immune responses. Optimal antitumor immune responses are considered to require the concomitant activation of both CD8(+) and CD4(+) T cells and the additional selective activation of CD4(+) T cells with helper, but not regulatory function. As optimal antitumor immune responses are generated by the concomitant activation of both T cell types, it is necessary for vaccine methods involving cytotoxic T-lymphocytes (CTLs) generation to possess a mechanism whereby antigen presenting cells can present administrated exogenous antigens on not only Major histocompatibility complex (MHC) class II, but also MHC class I molecules.
Ikehara
Yuzuru
Y
Molecular Medicine Team of Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8568, Japan. yuzuru-ikehara@aist.go.jp
Yamanaka
Masahiro
M
Yamaguchi
Takashi
T
D000818:Animals; D016503:Drug Delivery Systems; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D006801:Humans; D008081:Liposomes / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008358:Mannose / Q000494:pharmacology; D009844:Oligosaccharides / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014612:Vaccines / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D008081:Liposomes; D009844:Oligosaccharides; D014612:Vaccines; D008358:Mannose